How do clinicians prescribe bridging glucocorticoids in people starting or escalating disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a service evaluation survey
James A Prior, Edward Roddy, Ivonne Solis-Trapala, Nicola Cornwall, Clare Jinks, Abhishek Abhishek, Marwan Bukhari, James Galloway, Nicola Goodson, Sue Jowett, Samantha Hider · 2023
Read How do clinicians prescribe bridging glucocorticoids in people starting or escalating disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a service evaluation survey by James A Prior, Edward Roddy, Ivonne Solis-Trapala, Nicola Cornwall, Clare Jinks, Abhishek Abhishek, Marwan Bukhari, James Galloway, Nicola Goodson, Sue Jowett, Samantha Hider (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10665131.txt.
Description
n glucocorticoid prescribing route, dose, and duration of treatment. Dear Editor, The National Institute for Health and Care Excellence (NICE) RA guideline recommends bridging treatment with glucocorticoids in people starting DMARDs or biologics to reduce symptoms until the DMARD/biologic takes effect [1].
Catalog record
| CREATOR | James A Prior, Edward Roddy, Ivonne Solis-Trapala, Nicola Cornwall, Clare Jinks, Abhishek Abhishek, Marwan Bukhari, James Galloway, Nicola Goodson, Sue Jowett, Samantha Hider |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 7 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |